Glucagon's Impact on Kidney Blood Flow in Healthy Men
Glucagon
+ Glucagon+Exendin9-39
+ Sodium chloride
Urogenital Diseases+3
+ Female Urogenital Diseases and Pregnancy Complications
+ Kidney Diseases
Basic Science Study
Summary
Study start date: June 1, 2026
Actual date on which the first participant was enrolled.This study examines how a hormone called glucagon affects blood flow in the kidneys. Glucagon is essential for maintaining proper blood sugar levels and may influence kidney function, particularly in people with type 2 diabetes, who often have irregular glucagon levels. By understanding glucagon's impact on different parts of the kidney, like the cortex and medulla, the research aims to provide insights into kidney health and potentially improve treatments for those with diabetes or other related conditions. The study involves 10 healthy men between the ages of 20 and 60. Participants will have three different test days where they receive either glucagon, glucagon with a GLP-1 receptor blocker, or a placebo. Their kidney function and blood flow will be measured using MRI scans. This approach helps identify if glucagon's effects on the kidneys are due to changes in blood flow and whether these effects occur through specific receptors in the kidneys.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.10 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Basic Science Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Male
Biological sex of participants that are eligible to enroll.From 20 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives